We Need to Talk About Covid, Part 1

The quest for a “cure” for aging — a way to remain youthful, even as we get older — is a project as old as humanity. It’s also a big business; products, therapies and treatments intended to moderate or reverse aging are part of a $2 trillion global wellness market that’s only get ...  Show more

The presumptive Democratic Senate nominee from Maine on his controversies, contradictions and pitch for radical change. Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinter ...  Show more

The first in an unfolding miniseries - The Vaccine - tracking the progress of those tackling this historic challenge. We'll be making sense of the latest developments as they happen, taking an inside look at the vaccine industry, and learning from ...

The second of two episodes this week, taking a deep dive into the pharmaceutical industry.

Big drug companies have won plaudits for their work producing Covid vaccines within a year of the start of the pandemic. How much money are they making from them? And why are vacci ...

Apoorva Mandavilli, science and global health reporter for The New York Times, joins Dr. Bob to close out our three-part series marking one year of the pandemic. They discuss how journalism had to adapt to cover COVID-19, what she’s hearing from experts about a possible fourth wa ...  Show more

Andy explores the latest hazard to your health: the misinformation persuading people not to get vaccinated. US Surgeon General Dr. Vivek Murthy has declared war on misinformation and explains why he put out a rare Surgeon General's Advisory on the topic. Andy then covers the late ...  Show more